By turning GLP-1 treatment into a simple daily tablet, it provides a more familiar, convenient way to access effective weight-management support without the practical challenges often associated with injections
Produced in the intestines, GLP-1 supports stable blood sugar levels, slows digestion, promotes satiety (feeling of fullness), and prevents excess glucose production by the liver
(filing date: September 26, 2017
#HealthcareInnovation #GLP1 #DrugDelivery #LifeSciences #SystemsThinking To view or add a comment, sign in Copay accumulator programs, copay maximizer programs, and alternative funding programs (AFPs) are increasingly used by health plans and pharmacy benefit managers to control prescription drug costs
doi:10.1101/2024.01.18.24301500 Haran K, Johnson CE, Smith P, et al